Peptide-based tnf-α-binding decoy therapy mitigates lipopolysaccharide-induced liver injury in mice

Chao Yuan Chang, Hao Jen Hsu, Jossen Foo, Hung Jen Shih, Chun Jen Huang

研究成果: 雜誌貢獻文章同行評審

摘要

A peptide named SEM18, possessing structural similarity to the binding site of tumor necrosis factor (TNF)-α to TNF receptor 1 (TNFR1), was designed. We investigated whether the SEM18 peptide can mitigate lipopolysaccharide (LPS)-induced liver injury in mice. Adult male Balb/cJ mice received LPS (15 mg/kg; LPS group) or LPS plus SEM18 (LSEM group). Control groups were run simultaneously. At 2 h after LPS, the first dose of SEM18 (0.3 mg/kg) was administered, followed by three supplemental doses of SEM18 (0.15 mg/kg, every 2 h). At 24 h after LPS, surviving mice were euthanized for analyses. Compared with the LPS group, binding of TNF-α to TNFR1 in liver tissues was significantly lower in the LSEM group (p < 0.001). Plasma concentrations of aspartate transaminase and alanine transaminase, as well as Suzuki’s scores (liver damage assessment), wet/dry weight ratios, levels of polymorphonuclear neutrophil infiltration, and levels of mitochondrial injury in liver tissues, of the LSEM group were significantly lower than in the LPS group (all p < 0.05). Levels of necroptosis, pyroptosis, apoptosis, and autophagy upregulation in liver tissues in the LSEM group were also significantly lower than in the LPS group (all p < 0.05). Notably, exogenous TNF-α counteracted these effects of SEM18. SEM18 peptide mitigates LPS-induced liver injury in mice.

原文英語
文章編號280
頁(從 - 到)1-18
頁數18
期刊Pharmaceuticals
13
發行號10
DOIs
出版狀態已發佈 - 十月 2020

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

指紋 深入研究「Peptide-based tnf-α-binding decoy therapy mitigates lipopolysaccharide-induced liver injury in mice」主題。共同形成了獨特的指紋。

引用此